AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 27 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - The weak immunogenicity of tumor antigens may be due to regulatory T cells that suppress the response of self-reactive T cells to prevent development of autoimmune disease, according to a report in the Journal of Immunology.
"In mice, depletion of regulatory T cells by antibody therapy leads to more efficient tumor rejection," said Udaya K. Liyanage and colleagues at the Alvin J. Siteman Cancer Center in St. Louis. "Regulatory T cell-medicated suppression of antitumor immune responses may partly explain the poor clinical response to vaccine-based immunotherapy for human cancer."
The investigators determined levels of CD4- and CD25-expressing regulatory T cells (T[subscript]reg) in the peripheral blood lymphocytes (PBL), tumor-infiltrating lymphocytes, and local lymph node lymphocytes in 35 breast cancer patients, 30 pancreas cancer patients, and 35 healthy control subjects.
Significantly higher levels of T[subscript]reg as a percentage of the total CD4+ cell population were found in the breast cancer (16.6%, p
The T[subscript]reg secreted transforming growth factor beta (TGF-beta) and interleukin-10 (IL-10), but did not release interferon-gamma (IFN-gamma). When cells that normally do secrete IFN-gamma, such as activated CD8+ or CD4+25- cells, were exposed to T[subscript]reg, cell proliferation and IFN-gamma release was disrupted.
"We conclude that the prevalence of T[subscript]reg is increased in the peripheral blood as well as ...